C4X Discovery : International Clinical Trials features C4XD

C4X Discovery Holdings plc is a drug discovery company. The Company has a portfolio ranging from early-stage target opportunities to late-stage drug discovery programs. The Company has three commercially partnered programs with one candidate in clinical development. Its portfolio focuses on treatments for immuno-inflammatory diseases. The Company’s pipeline products include MALT-1 Inhibitor, a4B7 Integrin Inhibitor, IL-17A Inhibitor, NRF-2 Activator, and others. Its target identification platform (Taxonomy3) is used to analyze complex genetic datasets to identify and characterize drug target candidates. Taxonomy3 offers the potential for patient stratification in clinical trials, ensuring patient targeting and the potential for rescuing failed clinical trials or for drug repurposing. PatientSeek is its new platform that applies the mathematical approach of Taxonomy3 to stratify patients for treatments based on their genetics.